Bacillus Calmette Guerin Vaccine

• The Bacillus Calmette Guerin (BCG) vaccine is primarily used to prevent severe forms of tuberculosis (TB), especially in children.
• It is a live-attenuated vaccine derived from a strain of Mycobacterium bovis.
• The vaccine is widely administered in countries with a high incidence of TB.
• While effective against severe childhood TB, its efficacy against adult pulmonary TB varies.
• Common side effects are generally mild and localized, with serious adverse events being rare.

What is the Bacillus Calmette Guerin (BCG) Vaccine?

The Bacillus Calmette Guerin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is a live-attenuated vaccine, meaning it contains a weakened form of the Mycobacterium bovis bacterium, which is closely related to Mycobacterium tuberculosis, the pathogen responsible for human TB. The vaccine stimulates the immune system to develop protection against the disease. The development of the Bacillus Calmette Guerin vaccine explained its critical role in public health, especially in areas where TB is endemic. It was first developed by Albert Calmette and Camille Guérin in the early 20th century.

Uses and Benefits of the BCG Vaccine

The primary use of the BCG vaccine is to protect against tuberculosis, particularly severe forms in infants and young children, such as tuberculous meningitis and disseminated TB. The World Health Organization (WHO) recommends BCG vaccination for all infants in countries with a high incidence of TB (WHO, 2018). The BCG vaccine uses and benefits extend beyond TB prevention, as some studies suggest it may offer non-specific protective effects against other infections, though this area requires further research. For instance, it has been observed to reduce all-cause mortality in vaccinated infants in some settings.

A key benefit is its effectiveness in preventing life-threatening forms of TB in children. While its protection against pulmonary TB in adults is more variable, it significantly reduces the burden of severe disease in vulnerable populations:

• Prevention of severe childhood TB (meningitis, disseminated disease).
• Reduction in overall childhood mortality in high-burden areas.
• Potential non-specific protective effects against other infections.

BCG Vaccine Side Effects and Efficacy

Like all vaccines, the BCG vaccine can cause side effects, though most are mild and temporary. Common BCG vaccine side effects and efficacy considerations are important for understanding its public health impact. Typical local reactions at the injection site include redness, swelling, pain, and a small sore that may develop into an ulcer, which usually heals within weeks to months, leaving a characteristic scar.

Less common side effects can include enlarged lymph nodes in the armpit or neck, and very rarely, more severe reactions such as osteitis (bone infection) or disseminated BCG infection, particularly in individuals with compromised immune systems. Due to the risk of disseminated infection, BCG is contraindicated in people with severe immunodeficiency, including those with symptomatic HIV infection or undergoing immunosuppressive therapy (CDC, 2021).

The efficacy of the BCG vaccine against TB varies geographically and by strain of the vaccine, ranging from 0% to 80% (WHO, 2018). It is most effective in preventing severe forms of TB in infants and young children, with an estimated efficacy of 60-80% against tuberculous meningitis and disseminated TB. However, its efficacy against adult pulmonary TB is less consistent, which is a major reason why TB remains a global health challenge despite widespread BCG vaccination. Despite these variations, its role in preventing severe childhood disease makes it a vital component of global TB control strategies.